Efficacy of XXXX or @entity3866 in @entity1 with @entity1544 .

@entity1 @entity137 @entity66 @entity4562 @entity470 @entity9512 @entity1544 @entity74 @entity4149 @entity3866
INTRODUCTION: The aim of this study was to evaluate the feasibility of epidermal growth factor receptor- @entity4149 kinase inhibitor ( @entity470 -TKI) and @entity470 mutation frequency in advanced @entity1544 based on the data from our hospital. MATERIAL AND METHODS: The clinical data of 102 @entity1 with advanced @entity1544 who were admitted to Zhejiang Cancer Hospital from January 2007 to December 2011 were retrospectively analyzed. Survival analysis was evaluated by the Kaplan-Meier method. The @entity470 mutations were assessed in some of the @entity1 using the pyrosequencing assay. RESULTS: Nine @entity1 (8.8%) showed a partial response (PR), 28 (27.5%) achieved @entity66 ( @entity66 ), and 65 (63.7%) had @entity74 ( @entity74 ). The disease control rate was 36.3% and the median progression-free survival (PFS) was 1.93 months (95% CI: 1.57-2.29). The PFS in @entity1 who obtained disease control in the prior TKI was 8.63 months and 1.37 months in the disease progression cases (p < 0.001). No statistical differences in PFS were observed between @entity4562 and @entity3866 (2.0 months vs. 1.87 months, p = 0.76). The @entity137 associated with @entity470 -TKI were generally acceptable. In 74 @entity1 with adequate specimens for molecular analysis, 4 (5.4%) had @entity470 mutations (2 with deletions within exon 19 and 2 with @entity9512 mutation in exon 21). CONCLUSIONS: The @entity470 - @entity4149 kinase inhibitor seems to be a potential therapeutic option for treatment of advanced @entity1544 @entity1 . @entity3866 and @entity4562 had a similar efficacy in advanced @entity1544 . The frequency of @entity470 mutation was about 5.4% in our single hospital data.
